

## COMPANY OVERVIEW

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Additionally, Xenetic is leveraging PolyXen®, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen® has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and receives royalty payments under this agreement.

## RECENT NEWS

### [Xenetic Biosciences, Inc. Reports 2019 Year End Results and Provides Corporate Update](#)

Mar 27 2020, 9:00 AM EDT

### [Xenetic Biosciences' Webcast Replay from Noble Capital Markets' 16th Annual Investor Conference Presentation Now Available](#)

Feb 27 2020, 8:00 AM EST

## STOCK OVERVIEW

Symbol	XBIO
Exchange	Nasdaq
Market Cap	4.88m
Last Price	\$0.7765
52-Week Range	\$0.44 - \$20.736

04/08/2020 04:00 PM EDT

## INVESTOR RELATIONS

JTC Team, LLC.  
Jenene Thomas  
T: 833-475-8247  
[xbio@jtcir.com](mailto:xbio@jtcir.com)

## MANAGEMENT TEAM

**Jeffrey F. Eisenberg**  
Chief Executive Officer

**Curtis Lockshin, Ph.D.**  
Chief Scientific Officer

**James F. Parslow**  
Chief Financial Officer

## XENETIC BIOSCIENCES, INC.

40 Speen Street  
Suite 102  
Framingham, MA 01701  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.